Incyclix Bio
Andrew Beelen, MD, serves as Vice President of Clinical Development at Incyclix Bio and is an Industry Advisory Board Member at the Eshelman Institute for Innovation, UNC Eshelman School of Pharmacy. Previous roles include Executive Director and Vice President of Clinical Development at G1 Therapeutics, Senior Director of Clinical Development, and Sr. Medical Director focusing on Oncology Medical Strategy & Science at Quintiles. Andrew also held the position of Director of Clinical Research at Actavis. The educational background includes an MD in Medicine from Upstate Medical University (1993-1997) and further studies at the Geisel School of Medicine at Dartmouth (2000-2002).
This person is not in any teams
Incyclix Bio
Incyclix Bio, LLC is a next-generation cell cycle control company, advancing precision treatments that target the aberrant proliferation driving many cancers. The company’s lead compound is a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor nearing clinical stage. Incyclix Bio is a scientific leader in understanding cyclin-dependent kinases (CDKs) and their role in the cell cycle as attractive therapeutic targets across many tumor types, including ovarian, breast and lung cancers. Headquartered in Research Triangle Park, NC, Incyclix Bio is founded by pioneers in CDK inhibitor discovery, research and development.